News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
May 16, 2019DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019Printer Friendly Version
May 07, 2019DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a TrialPrinter Friendly Version
May 07, 2019DURECT Corporation Announces First Quarter 2019 Financial Results and Update of ProgramsPrinter Friendly Version
May 03, 2019DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial ResultsPrinter Friendly Version
Apr 25, 2019DURECT Appoints Two New Board MembersPrinter Friendly Version
Apr 01, 2019DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASHPrinter Friendly Version
Mar 27, 2019DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)Printer Friendly Version
Mar 21, 2019DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque PsoriasisPrinter Friendly Version
Mar 07, 2019DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of ProgramsPrinter Friendly Version
Mar 04, 2019DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference CallPrinter Friendly Version
Feb 27, 2019DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response LetterPrinter Friendly Version
Feb 21, 2019DURECT Corporation to Participate in the Berenberg NASH DayPrinter Friendly Version
Jan 07, 2019DURECT Corporation Provides Corporate UpdatePrinter Friendly Version
Jan 03, 2019DURECT Corporation Announces Investor Call to Provide Corporate UpdatePrinter Friendly Version
Dec 19, 2018Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in AdultsPrinter Friendly Version
Dec 17, 2018DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished ScientistPrinter Friendly Version
Nov 19, 2018DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH PatientsPrinter Friendly Version
Nov 07, 2018DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Nov 01, 2018DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference CallPrinter Friendly Version
Oct 25, 2018DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific MeetingsPrinter Friendly Version
Oct 01, 2018DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial OfficerPrinter Friendly Version
Sep 25, 2018DURECT to Present at the Cantor Fitzgerald Global Healthcare ConferencePrinter Friendly Version
Sep 18, 2018DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in TaiwanPrinter Friendly Version
Aug 30, 2018DURECT Announces Receipt of $5 Million Milestone Payment from IndiviorPrinter Friendly Version
Aug 27, 2018DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
Aug 06, 2018DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CIIPrinter Friendly Version
Aug 01, 2018DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Jul 30, 2018DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in AdultsPrinter Friendly Version
Jul 24, 2018DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference CallPrinter Friendly Version
Jun 26, 2018Results of FDA Advisory Committee Meeting for REMOXY® ERPrinter Friendly Version
May 09, 2018DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)Printer Friendly Version
May 02, 2018DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Apr 25, 2018DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic HepatitisPrinter Friendly Version
Apr 24, 2018DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference CallPrinter Friendly Version
Mar 29, 2018DURECT Corporation to Host Key Opinion Leader Call on Alcoholic HepatitisPrinter Friendly Version
Mar 20, 2018DURECT Announces FDA Advisory Committee Meeting for REMOXY® ERPrinter Friendly Version
Mar 01, 2018DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 26, 2018DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)Printer Friendly Version
Feb 22, 2018DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference CallPrinter Friendly Version
Feb 20, 2018DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)Printer Friendly Version
Feb 14, 2018DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain TherapeuticsPrinter Friendly Version
Dec 13, 2017DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly DepotPrinter Friendly Version
Nov 01, 2017DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Oct 26, 2017DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference CallPrinter Friendly Version
Oct 19, 2017DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy EndpointPrinter Friendly Version
Oct 02, 2017DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase AgreementPrinter Friendly Version
Sep 20, 2017DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical DevelopmentPrinter Friendly Version
Sep 05, 2017DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 08, 2017DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Aug 08, 2017ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in TaiwanPrinter Friendly Version
Aug 01, 2017DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference CallPrinter Friendly Version
Jun 22, 2017DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®Printer Friendly Version
Jun 19, 2017DURECT's Collaboration with Sandoz Clears HSR Review and is EffectivePrinter Friendly Version
May 10, 2017DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
May 08, 2017DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United StatesPrinter Friendly Version
May 04, 2017DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference CallPrinter Friendly Version
Apr 24, 2017DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017Printer Friendly Version
Apr 17, 2017DURECT to Present Clinical Data at the International Liver Congress™ 2017Printer Friendly Version
Apr 03, 2017DURECT to Present at the H.C. Wainwright NASH Investor ConferencePrinter Friendly Version
Mar 14, 2017DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 24, 2017DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference CallPrinter Friendly Version
Jan 30, 2017DURECT Corporation Announces Update on DUR-928 Development ProgramPrinter Friendly Version
Oct 31, 2016DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 31, 2016DURECT Corporation Announces Update on DUR-928 Development ProgramPrinter Friendly Version
Oct 21, 2016DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference CallPrinter Friendly Version
Sep 26, 2016DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CIIPrinter Friendly Version
Sep 06, 2016DURECT to Present at the Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
Aug 01, 2016DURECT Corporation Announces Second Quarter 2016 Financial Results and Update of ProgramsPrinter Friendly Version
Jul 25, 2016DURECT Corporation Invites You to Join its Second Quarter 2016 Earnings Conference CallPrinter Friendly Version
Jul 01, 2016DURECT Provides REMOXY® UpdatePrinter Friendly Version
Jun 28, 2016DURECT to Present at the Cantor Fitzgerald Healthcare ConferencePrinter Friendly Version
May 31, 2016DURECT to Present at the Jefferies Healthcare ConferencePrinter Friendly Version
May 19, 2016DURECT Announces FDA Advisory Committee Meeting for REMOXY®Printer Friendly Version
May 11, 2016DURECT Announces New REMOXY® Data being Presented at American Pain Society MeetingPrinter Friendly Version
May 05, 2016DURECT Corporation Announces First Quarter 2016 Financial Results and Update of ProgramsPrinter Friendly Version
Apr 29, 2016DURECT Announces Closing of Public Offering of Common StockPrinter Friendly Version
Apr 28, 2016DURECT Corporation Invites You to Join its First Quarter 2016 Earnings Conference CallPrinter Friendly Version
Apr 26, 2016DURECT Announces Pricing of Public Offering of Common StockPrinter Friendly Version
Apr 25, 2016DURECT Announces Proposed Public Offering of Common StockPrinter Friendly Version
Apr 12, 2016DURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016Printer Friendly Version
Apr 07, 2016DURECT Announces POSIMIR® Program UpdatePrinter Friendly Version
Mar 29, 2016DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug AdministrationPrinter Friendly Version
Feb 29, 2016DURECT Corporation Announces Fourth Quarter 2015 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 18, 2016DURECT Corporation Invites You to Join its Fourth Quarter 2015 Earnings Conference CallPrinter Friendly Version
Jan 28, 2016DURECT to Present at the BIO CEO & Investor ConferencePrinter Friendly Version
Jan 11, 2016DURECT Announces Initiation of DUR-928 Dosing in PatientsPrinter Friendly Version
Jan 06, 2016DURECT Announces Positive Phase 1 Data for DUR-928Printer Friendly Version
Nov 30, 2015DURECT to Present at the Oppenheimer Healthcare ConferencePrinter Friendly Version
Nov 05, 2015DURECT to Present at the Stifel Nicolaus Healthcare ConferencePrinter Friendly Version
Nov 02, 2015DURECT Corporation Announces Third Quarter 2015 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 26, 2015DURECT Corporation Invites You to Join its Third Quarter 2015 Earnings Conference CallPrinter Friendly Version
Oct 15, 2015DURECT to Present at the BIO Investor ForumPrinter Friendly Version
Aug 27, 2015DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 03, 2015DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of ProgramsPrinter Friendly Version
Jul 24, 2015DURECT Corporation Invites You to Join its Second Quarter 2015 Earnings Conference CallPrinter Friendly Version
Jun 29, 2015DURECT to Present at the Cantor Fitzgerald Healthcare ConferencePrinter Friendly Version
Jun 23, 2015DURECT Announces Plans for a New POSIDUR™ (SABER®-Bupivacaine) Clinical TrialPrinter Friendly Version
May 18, 2015DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 StudyPrinter Friendly Version
Apr 30, 2015DURECT Corporation Announces First Quarter 2015 Financial Results and Update of ProgramsPrinter Friendly Version
Apr 22, 2015DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference CallPrinter Friendly Version
Mar 30, 2015DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 StudyPrinter Friendly Version
Mar 02, 2015DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of ProgramsPrinter Friendly Version
Mar 02, 2015DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in DevelopmentPrinter Friendly Version
Feb 23, 2015DURECT Corporation Invites You to Join its Fourth Quarter 2014 Earnings Conference CallPrinter Friendly Version
Jan 29, 2015DURECT to Present at the BIO CEO & Investor ConferencePrinter Friendly Version
Dec 16, 2014DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology ProductPrinter Friendly Version
Dec 01, 2014DURECT to Present at the Oppenheimer Healthcare ConferencePrinter Friendly Version
Nov 11, 2014DURECT Provides Update on POSIDUR™ ProgramPrinter Friendly Version
Nov 03, 2014DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 27, 2014DURECT Provides Update on REMOXY® and POSIDUR™ ProgramsPrinter Friendly Version
Oct 24, 2014DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference CallPrinter Friendly Version
Oct 10, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the American Society of Anesthesiologists Annual MeetingPrinter Friendly Version
Aug 25, 2014DURECT to Present at the Rodman & Renshaw Investment ConferencePrinter Friendly Version
Aug 07, 2014DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of ProgramsPrinter Friendly Version
Jul 30, 2014DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference CallPrinter Friendly Version
Jun 26, 2014DURECT Secures $20 Million Debt FinancingPrinter Friendly Version
Jun 09, 2014DURECT to Present at The Wall Street Analyst Forum Institutional Investor ConferencePrinter Friendly Version
May 16, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia Research Society (IARS) Annual MeetingPrinter Friendly Version
May 07, 2014DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit MeetingPrinter Friendly Version
May 01, 2014DURECT Corporation Announces First Quarter 2014 Financial Results and Update of ProgramsPrinter Friendly Version
Apr 23, 2014DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference CallPrinter Friendly Version
Apr 01, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine MeetingPrinter Friendly Version
Feb 27, 2014DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 18, 2014DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor ConferencePrinter Friendly Version
Feb 12, 2014DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)Printer Friendly Version
Jan 07, 2014Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR® Pain PatchPrinter Friendly Version
Nov 13, 2013DURECT Announces Closing of Public Offering of Common StockPrinter Friendly Version
Nov 08, 2013DURECT Announces Pricing of Public Offering of Common StockPrinter Friendly Version
Nov 07, 2013DURECT Announces Proposed Public Offering of Common StockPrinter Friendly Version
Nov 04, 2013DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 28, 2013DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference CallPrinter Friendly Version
Oct 22, 2013Pfizer Proceeding with REMOXY® DevelopmentPrinter Friendly Version
Sep 27, 2013DURECT Announces Changes to its Board of DirectorsPrinter Friendly Version
Sep 03, 2013DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 05, 2013DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of ProgramsPrinter Friendly Version
Aug 01, 2013DURECT Announces Selection with Orient PHARMA of Lead Formulation for ORADUR®-MethylphenidatePrinter Friendly Version
Jul 26, 2013DURECT Corporation Invites You to Join its Second Quarter 2013 Earnings Conference CallPrinter Friendly Version
Jun 20, 2013DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR® (SABER®-Bupivacaine)Printer Friendly Version
May 10, 2013DURECT Announces Update on Remoxy®Printer Friendly Version
May 02, 2013DURECT Corporation Announces First Quarter 2013 Financial Results and Update of ProgramsPrinter Friendly Version
Apr 24, 2013DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference CallPrinter Friendly Version
Apr 16, 2013DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)Printer Friendly Version
Feb 28, 2013DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 22, 2013DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference CallPrinter Friendly Version
Feb 05, 2013DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Jan 03, 2013DURECT Announces Positive Results from Relday™ Phase 1 Clinical TrialPrinter Friendly Version
Dec 06, 2012DURECT Announces Pricing of Public Offering of Common StockPrinter Friendly Version
Nov 13, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Nov 05, 2012DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 30, 2012DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference CallPrinter Friendly Version
Aug 21, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 06, 2012DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
Aug 06, 2012DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative AnalgesiaPrinter Friendly Version
Jul 26, 2012DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference CallPrinter Friendly Version
May 03, 2012DURECT Corporation Announces First Quarter 2012 Financial Results and Update of ProgramsPrinter Friendly Version
May 03, 2012DURECT Announces Issuance of U.S. Patents Covering ORADUR® TechnologyPrinter Friendly Version
Apr 25, 2012DURECT Corporation Invites You to Join its First Quarter 2012 Earnings Conference CallPrinter Friendly Version
Mar 29, 2012DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR™Printer Friendly Version
Mar 01, 2012DURECT Corporation Announces Fourth Quarter and Year End 2011 Financial ResultsPrinter Friendly Version
Feb 24, 2012DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference CallPrinter Friendly Version
Feb 23, 2012DURECT to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Feb 07, 2012DURECT to Present at the BIO CEO & Investor ConferencePrinter Friendly Version
Jan 30, 2012DURECT Receives Back European Product Rights to POSIDUR™Printer Friendly Version
Jan 05, 2012DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)Printer Friendly Version
Nov 07, 2011DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Nov 03, 2011DURECT Corporation Announces Third Quarter 2011 Financial Results and Update of ProgramsPrinter Friendly Version
Oct 26, 2011DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference CallPrinter Friendly Version
Sep 06, 2011DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)Printer Friendly Version
Aug 31, 2011DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 04, 2011DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of ProgramsPrinter Friendly Version
Jul 28, 2011DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference CallPrinter Friendly Version
Jul 12, 2011Zogenix and DURECT Announce Development and License Agreement for Antipsychotic Product CandidatePrinter Friendly Version
Jun 24, 2011Pfizer Receives Complete Response Letter from FDA for REMOXY®Printer Friendly Version
Jun 03, 2011DURECT to Present at the Jefferies Healthcare ConferencePrinter Friendly Version
Jun 02, 2011DURECT Announces Resignation of Chief Medical OfficerPrinter Friendly Version
May 12, 2011DURECT to Present at the UBS Global Specialty Pharmaceuticals ConferencePrinter Friendly Version
May 05, 2011DURECT Corporation Announces First Quarter 2011 Financial Results and Update of ProgramsPrinter Friendly Version
Apr 28, 2011DURECT Corporation Invites You to Join its First Quarter 2011 Earnings Conference CallPrinter Friendly Version
Apr 11, 2011DURECT Announces ELADUR(R) (TRANSDUR(R)-Bupivacaine) Phase II Study Results in Chronic Low Back PainPrinter Friendly Version
Mar 02, 2011DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial ResultsPrinter Friendly Version
Mar 01, 2011DURECT to Present at Cowen and Company Health Care ConferencePrinter Friendly Version
Feb 24, 2011DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference CallPrinter Friendly Version
Feb 09, 2011DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR(TM) (SABER(TM)-Bupivacaine) and Amendment of the Nycomed AgreementPrinter Friendly Version
Feb 08, 2011DURECT Announces Launch of First FDA Approved SABER(TM)-Injectable Peptide ProductPrinter Friendly Version
Feb 07, 2011DURECT to Present at the BIO CEO & Investor ConferencePrinter Friendly Version
Jan 27, 2011REMOXY(R) New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011Printer Friendly Version
Dec 27, 2010REMOXY(R) New Drug Application ResubmittedPrinter Friendly Version
Nov 22, 2010DURECT to Present at the Piper Jaffray 2010 Health Care ConferencePrinter Friendly Version
Nov 08, 2010DURECT to Present at the Credit Suisse 2010 Healthcare ConferencePrinter Friendly Version
Nov 03, 2010DURECT Corporation Announces Third Quarter 2010 Financial ResultsPrinter Friendly Version
Nov 02, 2010DURECT Awarded $733,438 in Grants Under the Patient Protection and Affordable Care ProgramPrinter Friendly Version
Oct 27, 2010DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference CallPrinter Friendly Version
Sep 07, 2010DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Aug 04, 2010DURECT Corporation Announces Second Quarter 2010 Financial ResultsPrinter Friendly Version
Jul 29, 2010DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference CallPrinter Friendly Version
Jul 28, 2010DURECT to Present at the BMO Capital Markets Focus on Healthcare ConferencePrinter Friendly Version
Jul 01, 2010DURECT Corporation Secures $50 Million Committed Equity Financing FacilityPrinter Friendly Version
Jun 16, 2010DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)Printer Friendly Version
Jun 07, 2010DURECT Corporation Invites You to Join a Conference Call Today Regarding its POSIDUR(TM) Collaboration with HospiraPrinter Friendly Version
Jun 07, 2010Hospira and DURECT Sign Agreement to Develop and Commercialize POSIDUR™(SABER™-Bupivacaine) in the U.S. and CanadaPrinter Friendly Version
Jun 01, 2010DURECT to Present at the Jefferies Global Life Sciences ConferencePrinter Friendly Version
May 13, 2010DURECT to Present at the Rodman & Renshaw Global Healthcare ConferencePrinter Friendly Version
May 10, 2010DURECT Corporation Announces First Quarter 2010 Financial ResultsPrinter Friendly Version
May 04, 2010DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference CallPrinter Friendly Version
Apr 07, 2010DURECT Corporation Announces Commencement of Phase IIb ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) Clinical Trial by King PharmaceuticalsPrinter Friendly Version
Mar 17, 2010DURECT to Present at the Barclays Capital Global Healthcare ConferencePrinter Friendly Version
Mar 01, 2010DURECT to Present at the Cowen and Company Healthcare ConferencePrinter Friendly Version
Feb 24, 2010DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial ResultsPrinter Friendly Version
Feb 22, 2010DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand TerritoryPrinter Friendly Version
Feb 17, 2010DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference CallPrinter Friendly Version
Jan 19, 2010DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical TrialPrinter Friendly Version
Dec 17, 2009DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical ProgramPrinter Friendly Version
Nov 23, 2009DURECT to Present at the 21st Annual Piper Jaffray Health Care ConferencePrinter Friendly Version
Oct 29, 2009DURECT Corporation Announces Third Quarter 2009 Financial ResultsPrinter Friendly Version
Oct 26, 2009DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference CallPrinter Friendly Version
Sep 17, 2009DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Sep 11, 2009DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 MillionPrinter Friendly Version
Aug 27, 2009DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)Printer Friendly Version
Aug 18, 2009DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient PharmaPrinter Friendly Version
Aug 03, 2009DURECT Corporation Announces Second Quarter 2009 FinancialPrinter Friendly Version
Jul 28, 2009DURECT to Present at the BMO Capital Markets Healthcare ConferencePrinter Friendly Version
Jul 27, 2009DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference CallPrinter Friendly Version
Jul 07, 2009REMOXY(R) NDA UpdatePrinter Friendly Version
Jun 16, 2009DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate StrategyPrinter Friendly Version
May 06, 2009DURECT Corporation Announces First Quarter 2009 Financial ResultsPrinter Friendly Version
Apr 28, 2009DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference CallPrinter Friendly Version
Mar 16, 2009DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical ProgramPrinter Friendly Version
Mar 09, 2009DURECT to Participate in Cowen and Company Healthcare ConferencePrinter Friendly Version
Feb 27, 2009Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECTPrinter Friendly Version
Feb 09, 2009DURECT Corporation Announces Fourth Quarter and Year End 2008 Financial ResultsPrinter Friendly Version
Feb 02, 2009DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference CallPrinter Friendly Version
Dec 11, 2008Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)Printer Friendly Version
Nov 26, 2008DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Nov 03, 2008DURECT Corporation Announces Third Quarter 2008 Financial ResultsPrinter Friendly Version
Oct 29, 2008DURECT's Collaboration With Alpharma Clears HSR Review and Is EffectivePrinter Friendly Version
Oct 28, 2008DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Oct 27, 2008DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference CallPrinter Friendly Version
Sep 22, 2008Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain PatchPrinter Friendly Version
Sep 15, 2008DURECT Corporation Presenting at the 2008 UBS Global Life Sciences ConferencePrinter Friendly Version
Aug 27, 2008DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) TechnologyPrinter Friendly Version
Aug 12, 2008REMOXY(R) NDA Filing Accepted by FDA and Priority Review GrantedPrinter Friendly Version
Aug 05, 2008DURECT Corporation Announces Second Quarter 2008 Financial ResultsPrinter Friendly Version
Jul 30, 2008DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference CallPrinter Friendly Version
Jun 30, 2008ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic NeuralgiaPrinter Friendly Version
Jun 17, 2008DURECT's Convertible Notes Exchange into Equity at MaturityPrinter Friendly Version
Jun 10, 2008New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)Printer Friendly Version
Jun 06, 2008DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
May 21, 2008DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals ConferencePrinter Friendly Version
May 07, 2008DURECT Corporation Announces First Quarter 2008 Financial ResultsPrinter Friendly Version
Apr 29, 2008DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference CallPrinter Friendly Version
Apr 22, 2008DURECT to Participate in Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
Apr 07, 2008DURECT Provides Update on CHRONOGESIC(R) Research ProgramPrinter Friendly Version
Mar 11, 2008DURECT to Participate in Cowen Annual Healthcare ConferencePrinter Friendly Version
Feb 29, 2008DURECT to Participate in Susquehanna Financial Healthcare ConferencePrinter Friendly Version
Feb 05, 2008DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial ResultsPrinter Friendly Version
Feb 04, 2008DURECT to Present at BIO CEO Investor Conference 2008Printer Friendly Version
Jan 31, 2008DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference CallPrinter Friendly Version
Dec 18, 2007DURECT Announces Positive ELADUR(TM) Phase IIa Study ResultsPrinter Friendly Version
Dec 06, 2007Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)Printer Friendly Version
Dec 04, 2007DURECT to Present at Upcoming ConferencesPrinter Friendly Version
Nov 20, 2007DURECT to Present at Piper Jaffray Healthcare ConferencePrinter Friendly Version
Nov 01, 2007DURECT Corporation Announces Third Quarter 2007 Financial ResultsPrinter Friendly Version
Nov 01, 2007DURECT to Present at Upcoming ConferencesPrinter Friendly Version
Oct 30, 2007DURECT Corporation Invites You to Join Its Third Quarter 2007 Earnings Conference CallPrinter Friendly Version
Oct 16, 2007DURECT to Host Webcast in Conjunction with an Analyst's Day on October 17Printer Friendly Version
Oct 04, 2007DURECT to Present at 2007 BIO Investor ForumPrinter Friendly Version
Sep 20, 2007DURECT to Present at UBS Global Life Sciences ConferencePrinter Friendly Version
Sep 11, 2007DURECT to Present at Merriman Curhan Ford's Annual Investor SummitPrinter Friendly Version
Aug 29, 2007DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment ConferencePrinter Friendly Version
Aug 07, 2007DURECT Corporation Announces Second Quarter 2007 Financial ResultsPrinter Friendly Version
Jul 31, 2007DURECT Corporation Invites You to Join Its Second Quarter 2007 Earnings Conference Call on the WebPrinter Friendly Version
Jul 17, 2007DURECT Reports Positive Results from POSIDUR(TM) Phase IIb Hernia Trial, Triggering $8 million Milestone Payment from NycomedPrinter Friendly Version
Jul 11, 2007Patient Recruitment Completed for Pivotal Phase III Study of Remoxy(TM)Printer Friendly Version
Jun 27, 2007DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo PharmaceuticalsPrinter Friendly Version
Jun 21, 2007DURECT Corporation Presenting at the Jefferies Healthcare ConferencePrinter Friendly Version
Jun 11, 2007DURECT Corporation Presenting at the Sixth Annual Needham Biotechnology and Medical Technology ConferencePrinter Friendly Version
May 17, 2007DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical CorpPrinter Friendly Version
May 08, 2007DURECT Corporation Presenting at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare ConferencePrinter Friendly Version
May 07, 2007DURECT Corporation Announces First Quarter 2007 Financial ResultsPrinter Friendly Version
May 01, 2007DURECT Corporation Presenting at the 2007 UBS Global Generic and Specialty Pharmaceuticals ConferencePrinter Friendly Version
Apr 30, 2007DURECT Corporation Invites You to Join Its First Quarter 2007 Earnings Conference Call on the WebPrinter Friendly Version
Apr 09, 2007DURECT Corporation Presenting at the CIBC Biotechnology & Specialty Pharmaceuticals ConferencePrinter Friendly Version
Feb 28, 2007DURECT Corporation to Participate in Upcoming Healthcare ConferencesPrinter Friendly Version
Feb 12, 2007DURECT Corporation Presenting at the BIO CEO and Investor ConferencePrinter Friendly Version
Feb 08, 2007DURECT Corporation Announces Fourth Quarter and Year End 2006 Financial ResultsPrinter Friendly Version
Feb 05, 2007DURECT Establishes Corium as Manufacturer of TRANSDUR(TM)-BupivacainePrinter Friendly Version
Jan 30, 2007DURECT Corporation Invites You to Join Its Fourth Quarter and Year-End 2006 Conference Call on the WebPrinter Friendly Version
Jan 29, 2007DURECT Signs POSIDUR(TM) Manufacturing Agreement with HospiraPrinter Friendly Version
Jan 24, 2007DURECT Amends Agreement with Voyager Governing Memryte(TM)Printer Friendly Version
Jan 03, 2007DURECT Starts Phase II Dosing for TRANSDUR(TM)-Bupivacaine (DUR-843)Printer Friendly Version
Dec 18, 2006DURECT Corporation Appoints Dr. Terrence F. Blaschke to Its Board of DirectorsPrinter Friendly Version
Dec 11, 2006DURECT Corporation Announces Positive Phase I Study Results with New Product in DevelopmentPrinter Friendly Version
Nov 30, 2006Positive Phase I Results Reported for DURECT's Second Abuse-Resistant Opioid Pain MedicinePrinter Friendly Version
Nov 29, 2006DURECT and Nycomed Sign $202 Million Agreement to Develop and Commercialize POSIDUR(TM) in Europe and Other Select CountriesPrinter Friendly Version
Nov 03, 2006DURECT Corporation Announces Third Quarter 2006 Financial ResultsPrinter Friendly Version
Oct 31, 2006DURECT Corporation to Present at Upcoming ConferencesPrinter Friendly Version
Oct 27, 2006DURECT Corporation Invites You to Join Its Third Quarter 2006 Conference Call on the WebPrinter Friendly Version
Oct 19, 2006DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp.Printer Friendly Version
Oct 16, 2006DURECT Corporation Presenting at BIO InvestorForum 2006Printer Friendly Version
Sep 21, 2006DURECT Corporation Presenting at the UBS Global Life Sciences ConferencePrinter Friendly Version
Sep 12, 2006DURECT Corporation Appoints Matthew J. Hogan as Chief Financial OfficerPrinter Friendly Version
Aug 04, 2006DURECT Corporation Presenting at the Securities Research Associates Technology ConferencePrinter Friendly Version
Aug 02, 2006ORADUR(TM) Technology Milestone: New ORADUR-based Investigational Drug Candidate Commences Phase I Clinical ProgramPrinter Friendly Version
Jul 27, 2006DURECT Corporation Announces Second Quarter 2006 Financial ResultsPrinter Friendly Version
Jul 19, 2006DURECT Corporation Invites You to Join its Second Quarter 2006 Conference Call on the WebPrinter Friendly Version
Jul 10, 2006DURECT Corporation to Present at Upcoming Life Sciences ConferencesPrinter Friendly Version
Jun 23, 2006DURECT Corporation Presenting at the Jefferies Life Sciences ConferencePrinter Friendly Version
Jun 12, 2006DURECT Corporation Presenting at the Needham & Company Fifth Annual Biotechnology and Medical Technology ConferencePrinter Friendly Version
May 12, 2006DURECT Corporation Presenting at the Rodman & Renshaw 3rd Annual Global Healthcare ConferencePrinter Friendly Version
May 05, 2006ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-Based Oxycodone) Commences Pivotal Phase III ProgramPrinter Friendly Version
May 02, 2006DURECT Corporation Announces First Quarter 2006 Financial ResultsPrinter Friendly Version
May 02, 2006DURECT Corporation Appoints Peter Langecker Chief Medical OfficerPrinter Friendly Version
Apr 27, 2006DURECT Provides an Update on Its Post-Operative Pain Depot (SABER(TM)-Bupivacaine) ProgramPrinter Friendly Version
Apr 25, 2006DURECT Corporation Invites You to Join Its First Quarter 2006 Conference Call on the WebPrinter Friendly Version
Apr 19, 2006DURECT Corporation Presenting at the UBS Global Specialty Pharmaceuticals ConferencePrinter Friendly Version
Mar 30, 2006DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals ConferencePrinter Friendly Version
Feb 17, 2006ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase IIIPrinter Friendly Version
Feb 10, 2006DURECT Corporation Presenting at the BIO CEO and Investor ConferencePrinter Friendly Version
Feb 08, 2006DURECT Corporation Reports Fourth Quarter and Year End 2005 Financial ResultsPrinter Friendly Version
Feb 08, 2006DURECT Corporation Announces Anticipated Development Program Milestones for Fiscal Year 2006Printer Friendly Version
Jan 26, 2006DURECT to Expand Clinical Program to Additional Surgical Procedures and to Initiate U.S. Clinical Studies and for its Post-Operative Pain Relief DepotPrinter Friendly Version
Jan 23, 2006DURECT Corporation Invites You to Join Its Fourth Quarter and Year-End 2005 Conference Call on the WebPrinter Friendly Version
Jan 06, 2006DURECT Announces Promotions and Management ChangesPrinter Friendly Version
Jan 03, 2006DURECT Corporation Presenting at the JPMorgan 24th Annual Healthcare ConferencePrinter Friendly Version
Dec 26, 2005DURECT Announces Positive Preliminary Results from Transdermal Sufentanil Patch Study in PatientsPrinter Friendly Version
Nov 15, 2005DURECT Corporation Announces Exercise of Underwriters' Over-Allotment OptionPrinter Friendly Version
Nov 11, 2005DURECT Highlights Major Commercial Strategic Alliance for ORADUR(TM) Sustained Release Oral Gel-cap TechnologyPrinter Friendly Version
Nov 04, 2005DURECT Corporation Presenting at the Sixteenth Annual CIBC Healthcare ConferencePrinter Friendly Version
Nov 03, 2005DURECT Corporation Presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare ConferencePrinter Friendly Version
Nov 02, 2005DURECT Corporation Announces Pricing of Public OfferingPrinter Friendly Version
Oct 27, 2005DURECT Corporation Announces Proposed Public Offering of Common StockPrinter Friendly Version
Oct 18, 2005DURECT Announces Positive Preliminary Results From Its Phase II Study for Its Post-Operative Pain Relief DepotPrinter Friendly Version
Oct 14, 2005DURECT Corporation Announces Initiation of Dosing for Phase III Clinical Program for Memryte (DURIN(TM)-Leuprolide Implant) Program Under Development With Voyager PharmaceuticalsPrinter Friendly Version
Oct 13, 2005DURECT Corporation Announces Third Quarter 2005 Financial ResultsPrinter Friendly Version
Oct 07, 2005DURECT Corporation Invites You to Join Its Third Quarter 2005 Conference Call on the WebPrinter Friendly Version
Sep 21, 2005DURECT to Present Preliminary Phase II Clinical Data for Cohort 3 for Its Post-Operative Pain Relief Depot at American College of Surgeons ConferencePrinter Friendly Version
Sep 19, 2005DURECT Corporation Announces Completion of Dosing in Cohort 3 of its Phase II Study for its Post-Operative Pain Relief DepotPrinter Friendly Version
Sep 09, 2005DURECT Corporation Announces Positive Phase III Clinical Results for Remoxy, a Novel Oral Pain Medication using the ORADUR(TM) Gel-CapPrinter Friendly Version
Aug 08, 2005DURECT Corporation Presenting at Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research AssociatesPrinter Friendly Version
Aug 01, 2005DURECT Corporation Presenting at the Adams Harkness & Hill Annual Summer SeminarPrinter Friendly Version
Jul 22, 2005DURECT Corporation Announces Second Quarter 2005 Financial ResultsPrinter Friendly Version
Jul 22, 2005DURECT Plans to Reduce Convertible Debt Balance by $5 MillionPrinter Friendly Version
Jul 12, 2005DURECT Corporation Presenting at the C. E. Unterberg, Towbin Emerging Growth ConferencePrinter Friendly Version
Jul 11, 2005DURECT Announces Start of Dosing in Cohort 3 of Its Phase II Study for Its Post-Operative Pain Relief DepotPrinter Friendly Version
Jul 08, 2005DURECT Corporation Invites You to Join Its Second Quarter 2005 Conference Call on the WebPrinter Friendly Version
Jun 20, 2005DURECT Announces Preliminary Results from Cohort 2 of Its On-Going Phase II Study for Its Post-Operative Pain Relief DepotPrinter Friendly Version
May 24, 2005DURECT Corporation Presenting at the Friedman Billings Ramsey 9th Annual Growth Investor ConferencePrinter Friendly Version
May 03, 2005DURECT Corporation Announces First Quarter 2005 Financial Results and Update on Its Development ProgramsPrinter Friendly Version
Apr 19, 2005DURECT Corporation Invites You to Join Its First Quarter 2005 Conference Call on the WebPrinter Friendly Version
Apr 18, 2005Simon X. Benito Appointed to the Board of Directors of DURECT Corporation to Replace Albert L. ZesigerPrinter Friendly Version
Apr 11, 2005DURECT Corporation Announces Planned Departure of CFO and Director Thomas A. SchreckPrinter Friendly Version
Mar 29, 2005DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals ConferencePrinter Friendly Version
Mar 14, 2005DURECT Corporation and Endo Pharmaceuticals Sign Agreement to Develop and Commercialize DURECT'S Seven-Day Transdermal Pain PatchPrinter Friendly Version
Feb 24, 2005DURECT Corporation to Present at the Security Research Associates' Spring Technology & Life Sciences Investor ConferencePrinter Friendly Version
Feb 16, 2005DURECT Initiates Phase II Program for Its Sufentanil Patch ProductPrinter Friendly Version
Feb 10, 2005DURECT Corporation Reports Fourth Quarter and Year End 2004 Financial ResultsPrinter Friendly Version
Feb 10, 2005DURECT Completes Dosing of the Phase I Pharmacokinetic Study for Its Sufentanil Patch Product and of the First Cohort of the Phase II Study for Its Post-Operative Pain Relief DepotPrinter Friendly Version
Jan 28, 2005DURECT Corporation Announces Completion of Clinical Trial Enrollment for DURIN(TM)-Based Leuprolide Product CandidatePrinter Friendly Version
Jan 25, 2005DURECT Names Dr. Paula Mendenhall Senior Vice President of OperationsPrinter Friendly Version
Jan 20, 2005DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2004 Conference Call on the WebPrinter Friendly Version
Jan 12, 2005DURECT Corporation Announces Development Program Milestones for Fiscal Year 2005Printer Friendly Version
Jan 05, 2005DURECT Corporation Presents an Update to Its Development Pipeline and Hosts 1st Analyst LuncheonPrinter Friendly Version
Dec 23, 2004DURECT Corporation Announces Initiation of Phase III Studies for Remoxy, a Novel Oral Pain Medication using the ORADUR(TM) Gel-CapPrinter Friendly Version
Dec 20, 2004DURECT and Voyager Pharmaceutical Announce the Acceptance of DURIN(TM) Investigational New Drug Application and Clinical Protocol by the FDA for the Treatment of Alzheimer's DiseasePrinter Friendly Version
Nov 22, 2004DURECT Corporation Presenting at the Lazard 1st Annual Life Sciences ConferencePrinter Friendly Version
Nov 04, 2004DURECT Corporation Presenting at the Fifteenth Annual CIBC Healthcare ConferencePrinter Friendly Version
Oct 25, 2004DURECT Corporation Announces Third Quarter 2004 Financial Results and Update on Its Development ProgramsPrinter Friendly Version
Oct 25, 2004DURECT Initiates Phase II Clinical Program for Post-Operative Pain Relief DepotPrinter Friendly Version
Oct 22, 2004DURECT Initiates Phase I Trial for Its Proprietary Transdermal Sufentanil PatchPrinter Friendly Version
Oct 22, 2004DURECT Corporation Presenting at the C. E. Unterberg, Towbin Specialty Pharmaceutical ConferencePrinter Friendly Version
Oct 21, 2004DURECT Corporation Presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare ConferencePrinter Friendly Version
Oct 18, 2004DURECT Corporation Invites You to Join its Third Quarter 2004 Conference Call on the WebPrinter Friendly Version
Oct 12, 2004DURECT Corporation Presenting at the HealthpointCapital Biomaterials SummitPrinter Friendly Version
Oct 05, 2004DURECT Corporation Presenting at BIO Emerging Company Investor ForumPrinter Friendly Version
Sep 16, 2004DURECT Corporation Presenting at the First Annual Merriman Curhan Ford & Co. Investor SummitPrinter Friendly Version
Aug 09, 2004DURECT Corporation Presenting at the Halpern Capital Summer Growth Stock ConferencePrinter Friendly Version
Aug 02, 2004DURECT Corporation Presenting at the Adams Harkness & Hill's 24th Summer SeminarPrinter Friendly Version
Jul 21, 2004DURECT Corporation Announces Second Quarter 2004 Financial Results and Update on Its Development ProgramsPrinter Friendly Version
Jul 15, 2004DURECT Corporation Invites You to Join Its Second Quarter 2004 Conference Call on the WebPrinter Friendly Version
Jul 06, 2004DURECT Announces Positive Clinical Results With Its ORADUR(TM) Sustained Release Oral Gel-Cap TechnologyPrinter Friendly Version
Jun 21, 2004DURECT Corporation and NeuroSystec Corporation Announce Exclusive Agreement to Develop Treatments for Certain Inner Ear Disorders Including TinnitusPrinter Friendly Version
May 06, 2004DURECT Corporation Presenting at the Rodman & Renshaw Healthcare ConferencePrinter Friendly Version
Apr 27, 2004DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals ConferencePrinter Friendly Version
Apr 22, 2004DURECT Corporation Announces First Quarter 2004 Financial ResultsPrinter Friendly Version
Apr 14, 2004DURECT Corporation Invites You to Join Its First Quarter 2004 Conference Call on the WebPrinter Friendly Version
Mar 23, 2004Michael D. Casey Appointed to the Board of Directors of DURECT CorporationPrinter Friendly Version
Feb 24, 2004DURECT Corporation Presenting at the 4th Annual Smith Barney Citigroup Specialty Pharmaceuticals ConferencePrinter Friendly Version
Feb 13, 2004DURECT Announces Promotions and Management ChangesPrinter Friendly Version
Feb 10, 2004DURECT Corporation Reports Fourth Quarter 2003 and Year End Financial ResultsPrinter Friendly Version
Jan 27, 2004DURECT Corporation Invites You to Join Its Fourth Quarter and Year End 2003 Conference Call on the WebPrinter Friendly Version
Jan 06, 2004DURECT Corporation Presenting at the JPMorgan H&Q 22nd Annual Healthcare ConferencePrinter Friendly Version
Nov 07, 2003DURECT Corporation Presenting at The CIBC World Markets 14th Annual Healthcare ConferencePrinter Friendly Version
Nov 06, 2003DURECT Corporation Announces Third Quarter 2003 Financial ResultsPrinter Friendly Version
Nov 06, 2003DURECT Announces Positive Clinical Results for its Post-operative Pain Relief Depot using the SABER(TM) Delivery SystemPrinter Friendly Version
Oct 20, 2003DURECT Corporation Invites You to Join Its Third Quarter 2003 Conference Call On the WebPrinter Friendly Version
Oct 16, 2003DURECT Announces Update to CHRONOGESIC ProgramPrinter Friendly Version
Oct 09, 2003DURECT Initiates Manufacture of Clinical Product for its CHRONOGESIC(R) (Sufentanil) Pain Therapy ProductPrinter Friendly Version
Sep 23, 2003Jon S. Saxe Appointed to the Board of Directors of DURECT CorporationPrinter Friendly Version
Sep 03, 2003DURECT Corporation Presenting at the Thomas Weisel Partners Healthcare ConferencePrinter Friendly Version
Sep 02, 2003DURECT Corporation Completes Validation of Terminal Sterilization Manufacturing Process for its CHRONOGESIC (sufentanil) Pain Therapy ProductPrinter Friendly Version
Aug 05, 2003DURECT Corporation Presenting at the Adams Harkness & Hill's 23rd Summer SeminarPrinter Friendly Version
Jul 24, 2003DURECT Corporation Announces Second Quarter 2003 Financial ResultsPrinter Friendly Version
Jul 11, 2003Initial Purchaser Exercises Option to Purchase an Additional $10 Million Of the $50 Million of 6.25% Convertible NotesPrinter Friendly Version
Jul 11, 2003DURECT Corporation Invites You to Join its Second Quarter 2003 Conference Call on the WebPrinter Friendly Version
Jun 13, 2003DURECT Corporation Announces Pricing of $50 Million Convertible Note OfferingPrinter Friendly Version
Jun 11, 2003DURECT Corporation Announces Proposed $50 Million Convertible Debt OfferingPrinter Friendly Version
Jun 10, 2003DURECT Initiates Human Clinical Testing for Its Post-operative Pain Relief Depot Using the SABER(TM) Delivery SystemPrinter Friendly Version
May 15, 2003DURECT Corporation Presenting at Friedman Billings Ramsey 7th Annual Technology & Growth Investor ConferencePrinter Friendly Version
Apr 28, 2003DURECT Corporation Announces First Quarter 2003 Financial ResultsPrinter Friendly Version
Apr 28, 2003DURECT Corporation Presenting at The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals ConferencePrinter Friendly Version
Apr 15, 2003DURECT Corporation Invites You to Join Its First Quarter 2003 Conference Call on the WebPrinter Friendly Version
Jan 28, 2003DURECT Corporation Reports Fourth Quarter 2002 and Year End Financial ResultsPrinter Friendly Version
Jan 15, 2003DURECT Corporation Invites You to Join Its Fourth Quarter And Year End 2002 Conference Call on the WebPrinter Friendly Version
Jan 14, 2003Pain Therapeutics and DURECT Corporation Announce Exclusive Agreement to Formulate Certain Long-Acting Opioid DrugsPrinter Friendly Version
Jan 02, 2003DURECT Corporation Presenting at the JPMorgan H&Q 21st Annual Healthcare ConferencePrinter Friendly Version
Dec 27, 2002David R. Hoffmann Appointed to the Board of Directors of DURECT CorporationPrinter Friendly Version
Nov 22, 2002DURECT Corporation Increases Focus on Product Development Activities and Reducing CostsPrinter Friendly Version
Nov 19, 2002BioPartners and DURECT Corporation Enter Into Agreement for Development Of Sustained Release Interferon AlphaPrinter Friendly Version
Nov 14, 2002DURECT Corporation and Thorn BioScience LLC Expand Existing Licensing Agreement to Develop Veterinary ProductsPrinter Friendly Version
Nov 12, 2002DURECT Corporation Reports Third Quarter 2002 Financial ResultsPrinter Friendly Version
Nov 12, 2002DURECT Corporation and ALZA Corporation Amend Licensing AgreementPrinter Friendly Version
Nov 11, 2002DURECT Corporation Postpones Its Third Quarter 2002 Conference CallPrinter Friendly Version
Nov 11, 2002Endo Pharmaceuticals and DURECT Corporation Agree To Collaborate on Treatment in Pain ManagementPrinter Friendly Version
Oct 30, 2002DURECT Corporation Presenting at The CIBC World Markets 13th Annual Health Care ConferencePrinter Friendly Version
Oct 16, 2002DURECT Corporation Invites You to Join Its Third Quarter 2002 Conference Call on the WebPrinter Friendly Version
Oct 04, 2002DURECT Corporation Presenting at The UBS Warburg Global Life Sciences ConferencePrinter Friendly Version
Aug 26, 2002DURECT Corporation Delays Enrolling Additional Patients in Its Phase III Clinical Trial for CHRONOGESIC Pending Clinical Trial Protocol AmendmentsPrinter Friendly Version
Aug 05, 2002DURECT Corporation Presenting at The Adams, Harkness & Hill's 22nd Annual Summer SeminarPrinter Friendly Version
Jul 29, 2002DURECT Corporation Reports Second Quarter 2002 Financial ResultsPrinter Friendly Version
Jul 29, 2002DURECT Corporation and Voyager Pharmaceutical Corporation Sign Development and Commercialization Agreement to Develop Treatment for Alzheimer's DiseasePrinter Friendly Version
Jul 09, 2002DURECT Initiates Pivotal Phase III Program for the CHRONOGESIC(TM) (Sufentanil) Pain Therapy SystemPrinter Friendly Version
Jul 08, 2002DURECT Corporation Invites You to Join Its Second Quarter 2002 Conference Call on the WebPrinter Friendly Version
Jun 11, 2002DURECT Corporation to Present at the Goldman Sachs Twenty - Third Annual Global Healthcare ConferencePrinter Friendly Version
Jun 05, 2002DURECT Corporation Presenting at the UBS Warburg Global Specialty Pharmaceuticals ConferencePrinter Friendly Version
Apr 29, 2002DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals ConferencePrinter Friendly Version
Apr 24, 2002DURECT Corporation Reports First Quarter 2002 Financial ResultsPrinter Friendly Version
Apr 08, 2002DURECT Corporation Invites You to Join its First Quarter 2002 Conference Call on the WebPrinter Friendly Version
Apr 02, 2002DURECT Corporation Files IND for the Long Term Treatment of AsthmaPrinter Friendly Version
Mar 27, 2002DURECT Corporation and Cardinal Health Announce Collaboration to Research And Develop Long Acting Gel-Cap Products Using the SABER(TM) Delivery SystemPrinter Friendly Version
Mar 18, 2002DURECT Corporation Announces Positive Results of Pilot Phase III Study For The CHRONOGESIC(TM) ProductPrinter Friendly Version
Jan 30, 2002DURECT Corporation Reports Fourth Quarter 2001 and Year End Financial ResultsPrinter Friendly Version
Jan 23, 2002DURECT Corporation Sponsors Symposium on Novel Drug Delivery Technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS)Printer Friendly Version
Jan 14, 2002DURECT Corporation Invites You to Join its Fourth Quarter and Year End 2001 Conference Call on the WebPrinter Friendly Version
Jan 04, 2002DURECT Corporation Presenting at the JPMorgan H&Q 20th Annual Healthcare ConferencePrinter Friendly Version
Nov 16, 2001Janssen Pharmaceutica Enters Into Exclusive Marketing Discussions With DURECT Corporation for Chronogesic(TM)Printer Friendly Version
Nov 01, 2001DURECT Corporation Presenting at the CIBC World Markets Twelfth Annual Health Care ConferencePrinter Friendly Version
Nov 01, 2001DURECT Corporation Reports Initiation of Phase III Program for Chronogesic(TMPrinter Friendly Version
Oct 31, 2001DURECT Corporation Reports Third Quarter 2001 Financial ResultsPrinter Friendly Version
Oct 25, 2001DURECT Announces Results From Research Collaboration With the University of Maastricht Showing Blood Flow to the Ischemic Heart Restored Following Local Administration of Growth FactorsPrinter Friendly Version
Oct 16, 2001DURECT Corporation Presenting at the Techvest 3rd Annual Healthcare ConferencePrinter Friendly Version
Oct 15, 2001DURECT Corporation Invites You to Join its Third Quarter 2001 Conference Call on the WebPrinter Friendly Version
Sep 24, 2001DURECT Corporation Announces Promotions of OfficersPrinter Friendly Version
Sep 05, 2001DURECT Announces Positive Phase II Results on Chronogesic(TM) For Long-Term Pain ReliefPrinter Friendly Version
Aug 24, 2001DURECT Corporation Invites You to Join Its Phase II Trial Results Conference Call on the WebPrinter Friendly Version
Jul 30, 2001DURECT Corporation Reports Second Quarter 2001 Financial ResultsPrinter Friendly Version
Jul 19, 2001DURECT Corporation Invites You to Join its Second Quarter 2001 Conference Call on the WebPrinter Friendly Version
Jul 06, 2001Durect Corporation Adopts Stockholder Rights PlanPrinter Friendly Version
Jun 29, 2001DURECT Announces Chronogesic Preliminary Clinical Results of Phase II TrialPrinter Friendly Version
Jun 25, 2001DURECT Announces Filing of Special 510(k) Application for its New Generation IntraEAR(R) Ear Catheter Product and Approval of Physician Sponsored Investigational New Drug Application for Treatment of Meniere's DiseasePrinter Friendly Version
Jun 25, 2001DURECT Announces Filing of Special 510(k) Application for its New Generation IntraEAR(R) Ear Catheter Product and Approval of Physician Sponsored Investigational New Drug Application for Treatment ...Printer Friendly Version
May 24, 2001DURECT Completes Construction of Commercial Manufacturing FacilityPrinter Friendly Version
May 11, 2001DURECT Corporation Completes the Clinical Portion of Phase II Clinical Trial for DUROS SufentanilPrinter Friendly Version
Apr 30, 2001DURECT Corporation Reports First Quarter 2001 Financial ResultsPrinter Friendly Version
Apr 30, 2001DURECT Corporation Announces Acquisition of Southern BioSystems, IncPrinter Friendly Version
Apr 24, 2001DURECT Corporation Invites You to Join Its First Quarter 2001 Conference Call on the WebPrinter Friendly Version
Apr 03, 2001Dennis M. Fisher, MD Named Vice President for Medical AffairsPrinter Friendly Version
Mar 27, 2001DURECT Corporation Announces Long-Term Drug Supply Agreement With MallinckrodtPrinter Friendly Version
Mar 09, 2001DURECT Corporation Announces Completion of Patient Enrollment in Phase II Clinical Trial for DUROS SufentanilPrinter Friendly Version
Mar 01, 2001Armand P. Neukermans Appointed to the Board of Directors of DURECT CorporationPrinter Friendly Version
Mar 01, 2001DURECT Corporation Invites You to View Its Salomon Smith Barney Specialty Pharmaceuticals Conference Investor PresentationPrinter Friendly Version
Feb 16, 2001DURECT Corporation Announces Earnings and Reports Strong Progress on Its BusinessPrinter Friendly Version
Feb 15, 2001DURECT Corporation Reports Fourth Quarter 2000 and Year End Financial ResultsPrinter Friendly Version
Feb 07, 2001DURECT Announces Acceleration of Completion of Patient Enrollment in its Phase II Clinical Trial for DUROS SufentanilPrinter Friendly Version
Jan 24, 2001Evelyn R. Robledo Named Vice President of Quality Assurance and CompliancePrinter Friendly Version
Jan 22, 2001DURECT Corporation Invites You to Join its Fourth Quarter Conference Call on the WebPrinter Friendly Version
Dec 12, 2000DURECT Corporation Invites You to View Its Chase H&Q Healthcare Conference Investor PresentationPrinter Friendly Version
Dec 11, 2000DURECT Corporation Enrolls Patients in Phase II Clinical Trial for DUROS SufentanilPrinter Friendly Version
Nov 13, 2000DURECT Corporation Reports Third Quarter 2000 Financial ResultsPrinter Friendly Version
Nov 07, 2000DURECT Corporation Invites You to Join Its Third Quarter Conference Call on the WebPrinter Friendly Version
Nov 02, 2000DURECT Corporation Announces Exercise of Over-allotment Option in Initial Public OfferingPrinter Friendly Version
Oct 23, 2000DURECT Corporation Announces Commencement of Construction of Commercial Manufacturing Facility in Cupertino, CAPrinter Friendly Version
Sep 28, 2000DURECT Announces Initial Public OfferingPrinter Friendly Version
Apr 20, 2000DURECT Announces Filing of Registration StatementPrinter Friendly Version
Oct 06, 1999DURECT Corporation Acquires IntraEAR, Inc.Printer Friendly Version
Aug 12, 1999Genetronics Announces Election of Dr. Felix Theeuwes, A Drug Delivery Pioneer, to Its Board of DirectorsPrinter Friendly Version
Aug 02, 1999Pharmaceutical Firm Developing Therapies for Promising New Drug Delivery SystemPrinter Friendly Version